Septerna (NASDAQ:SEPN) Stock Rating Upgraded by Guggenheim

Septerna (NASDAQ:SEPN) was upgraded by research analysts at Guggenheim to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Several other research analysts have also commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Cantor Fitzgerald restated an “overweight” rating and set a $60.00 price target on shares of Septerna in a research report on Tuesday, March 10th. Stifel Nicolaus initiated coverage on Septerna in a research report on Friday, May 1st. They set a “buy” rating and a $43.00 price target for the company. Truist Financial raised their price target on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Finally, Wall Street Zen lowered Septerna from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.78.

Septerna Stock Up 11.7%

SEPN opened at $34.03 on Thursday. Septerna has a 52 week low of $9.85 and a 52 week high of $34.19. The business has a fifty day simple moving average of $26.75 and a 200-day simple moving average of $26.73. The firm has a market cap of $1.53 billion, a P/E ratio of -42.01 and a beta of 2.39.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The business had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Sell-side analysts expect that Septerna will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In related news, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total value of $97,360.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $4,240,247.06. This trade represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Samira Shaikhly sold 11,798 shares of Septerna stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the transaction, the insider owned 793 shares of the company’s stock, valued at approximately $23,837.58. This trade represents a 93.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 21,733 shares of company stock valued at $623,707. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Group One Trading LLC boosted its holdings in Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares during the period. Global Retirement Partners LLC acquired a new stake in Septerna in the fourth quarter valued at $35,000. Russell Investments Group Ltd. acquired a new stake in Septerna in the third quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Septerna in the fourth quarter valued at $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Septerna in the fourth quarter valued at $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.